Viracta Therapeutics (VIRX) Competitors $0.19 -0.01 (-4.89%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VIRX vs. ACXP, EQ, LGVN, ENLV, NAII, MIRA, ICCC, INKT, ITRM, and PLURShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Acurx Pharmaceuticals (ACXP), Equillium (EQ), Longeveron (LGVN), Enlivex Therapeutics (ENLV), Natural Alternatives International (NAII), MIRA Pharmaceuticals (MIRA), ImmuCell (ICCC), MiNK Therapeutics (INKT), Iterum Therapeutics (ITRM), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Acurx Pharmaceuticals Equillium Longeveron Enlivex Therapeutics Natural Alternatives International MIRA Pharmaceuticals ImmuCell MiNK Therapeutics Iterum Therapeutics Pluri Viracta Therapeutics (NASDAQ:VIRX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media refer more to VIRX or ACXP? In the previous week, Viracta Therapeutics had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 1 mentions for Viracta Therapeutics and 0 mentions for Acurx Pharmaceuticals. Viracta Therapeutics' average media sentiment score of 0.46 beat Acurx Pharmaceuticals' score of 0.00 indicating that Viracta Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Viracta Therapeutics Neutral Acurx Pharmaceuticals Neutral Does the MarketBeat Community prefer VIRX or ACXP? Viracta Therapeutics received 16 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 92.31% of users gave Acurx Pharmaceuticals an outperform vote while only 71.79% of users gave Viracta Therapeutics an outperform vote. CompanyUnderperformOutperformViracta TherapeuticsOutperform Votes2871.79% Underperform Votes1128.21% Acurx PharmaceuticalsOutperform Votes1292.31% Underperform Votes17.69% Which has stronger valuation and earnings, VIRX or ACXP? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.16-0.17Acurx PharmaceuticalsN/AN/A-$14.58M-$1.16-1.60 Is VIRX or ACXP more profitable? Acurx Pharmaceuticals' return on equity of -371.20% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -449.60% -92.47% Acurx Pharmaceuticals N/A -371.20%-219.01% Which has more volatility and risk, VIRX or ACXP? Viracta Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500. Do institutionals & insiders believe in VIRX or ACXP? 31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend VIRX or ACXP? Viracta Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 2,729.22%. Acurx Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 545.16%. Given Viracta Therapeutics' higher probable upside, analysts clearly believe Viracta Therapeutics is more favorable than Acurx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryViracta Therapeutics beats Acurx Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.95M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.179.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.595.324.665.02Net Income-$51.06M$153.56M$119.06M$225.46M7 Day Performance-26.36%0.13%0.80%0.37%1 Month Performance-16.21%15.23%5.65%3.57%1 Year Performance-69.14%41.14%36.75%29.43% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics3.4253 of 5 stars$0.19-4.9%$5.50+2,729.2%-70.1%$7.95MN/A-0.1720Positive NewsGap DownACXPAcurx Pharmaceuticals1.2429 of 5 stars$1.86-1.1%$12.00+545.2%-63.3%$30.23MN/A-1.603Positive NewsEQEquillium2.4304 of 5 stars$0.83-3.6%$5.00+502.4%+67.6%$29.40M$36.08M-3.3240Short Interest ↑News CoverageLGVNLongeveron3.1085 of 5 stars$2.03-2.9%$8.00+294.1%-90.1%$29.15M$710,000.00-0.2323Upcoming EarningsENLVEnlivex Therapeutics3.4122 of 5 stars$1.35flat$6.00+344.4%+2.4%$28.90MN/A-1.1470News CoverageNAIINatural Alternatives International1.0223 of 5 stars$4.53-0.9%N/A-24.4%$28.09M$113.80M-3.68290Analyst ForecastMIRAMIRA Pharmaceuticals3.2265 of 5 stars$1.90-13.2%$14.00+636.8%+25.8%$28.08MN/A-2.792ICCCImmuCell0.6704 of 5 stars$3.58-0.8%N/A-29.9%$28.04M$23.22M-6.7575Positive NewsINKTMiNK Therapeutics1.9469 of 5 stars$0.71-0.7%$9.00+1,169.4%-30.5%$28.03MN/A-1.4530News CoverageGap UpITRMIterum Therapeutics2.8355 of 5 stars$1.22-5.4%$5.00+309.8%+67.1%$27.71MN/A-0.6110Gap UpHigh Trading VolumePLURPluri0.7863 of 5 stars$4.85-3.2%N/A+14.4%$26.53M$330,000.00-0.82150Gap Down Related Companies and Tools Related Companies ACXP Alternatives EQ Alternatives LGVN Alternatives ENLV Alternatives NAII Alternatives MIRA Alternatives ICCC Alternatives INKT Alternatives ITRM Alternatives PLUR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
